NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

NOVARTIS OCTREOTIDE LAR octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis octreotide lar octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite p

novartis pharmaceuticals australia pty ltd - octreotide -

Fluorescein Novartis Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

fluorescein novartis

novartis pharmaceuticals australia pty ltd - fluorescein sodium -

CO-DIOVAN 8012.5 MG FILM COATED TABLETS Israeli - Kiingereza - Ministry of Health

co-diovan 8012.5 mg film coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Israeli - Kiingereza - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 16025 MG FILM-COATED TABLETS Israeli - Kiingereza - Ministry of Health

co-diovan 16025 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

SANDOSTATIN LAR 30 MG Israeli - Kiingereza - Ministry of Health

sandostatin lar 30 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

SANDOSTATIN LAR 20 MG Israeli - Kiingereza - Ministry of Health

sandostatin lar 20 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

SANDOSTATIN LAR 10 MG Israeli - Kiingereza - Ministry of Health

sandostatin lar 10 mg

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

SIMULECT 20 MG Israeli - Kiingereza - Ministry of Health

simulect 20 mg

novartis israel ltd - basiliximab - powder and solvent for solution for injection/infusion - basiliximab 20 mg/vial - basiliximab - basiliximab - prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression